Why Evidence Matters in Public Health Communication
A recent article published by Stanford Medicine, “Nicotine Pouches: The Tobacco Industry’s Latest Ploy?”, raises legitimate concerns about nicotine addiction and youth uptake. These are important issues that deserve serious attention and are shared concerns across the public health community.
However, effective public health communication should present the full evidence base. In focusing almost exclusively on nicotine pouches as a “latest ploy” by the tobacco industry, the article overlooks important scientific evidence on relative risk, the evolving regulatory landscape, and the role that lower-risk nicotine products may play for adults who smoke.
For GINN, protecting young people and supporting adult harm reduction are complementary public health objectives, not competing ones.
Harm Reduction Requires Context
No nicotine product is risk-free.
Nicotine is addictive, and young people should never use nicotine products. Strong age verification, responsible marketing, and effective enforcement are essential.
At the same time, it is equally important to distinguish between nicotine addiction and the diseases caused by smoking.
The overwhelming burden of smoking-related disease results primarily from combustion. Tobacco-free nicotine pouches eliminate combustion and tobacco leaf, substantially reducing exposure to many of the toxicants responsible for smoking-related illness. Multiple scientific reviews and health-risk assessments, including recent reviews published in Addiction, Regulatory Toxicology and Pharmacology, and the German Federal Institute for Risk Assessment (BfR), recognise this important distinction.
Ignoring these differences risks reinforcing the misconception that all nicotine products present equivalent levels of harm, an outcome that may discourage adult smokers from considering lower-risk alternatives.
A More Balanced Reading of the Evidence
The Stanford article rightly highlights concerns around nicotine dependence, particularly among adolescents. Yet the wider evidence presents a more nuanced picture.
Emerging clinical studies suggest that nicotine pouches can reduce cigarette consumption and cravings among some adult smokers while generally demonstrating a substantially lower toxicant profile than combustible cigarettes. At the same time, researchers continue to emphasise the need for longer-term studies examining cessation outcomes, patterns of use, and potential adverse effects.
The current evidence therefore supports careful regulation, ongoing surveillance, and continued research, not simplistic conclusions that present nicotine pouches solely as another form of combustible tobacco.
Risk Is Real but It Is Also Relative
One aspect of the Stanford article that deserves additional context is its emphasis on very high-strength nicotine pouches, including references to products containing nicotine levels far above those commonly found in the regulated market.
We believe this places disproportionate emphasis on a relatively small subset of products without adequately reflecting the wider nicotine pouch category.
Most mainstream nicotine pouches sold across Europe and many available in the United States, typically fall within a moderate nicotine range, while regulators are increasingly examining product standards, nicotine-strength limits, and appropriate labelling requirements. High-strength products are already the subject of growing regulatory scrutiny and should not be viewed as representative of the category as a whole.
We support proportionate measures that address nicotine strength where appropriate, alongside product standards, clear labelling, child-resistant packaging, and responsible marketing.
By focusing primarily on extreme-strength examples, the Stanford article risks presenting an alarmist picture that does not fully reflect either the diversity of products available or the direction of evidence-based regulation.
The more important policy question is not whether nicotine pouches should exist, but how they should be regulated to maximise public health benefits while minimising potential risks.
Youth Protection and Harm Reduction Can Coexist
GINN agrees unequivocally that nicotine pouches should never be marketed or sold to minors.
However, protecting young people does not require disregarding the needs of millions of adults who continue to smoke.
Targeted measures, including strict age verification, responsible packaging standards, restrictions on youth-oriented branding, and effective enforcement against irresponsible marketing, can reduce youth access while preserving lower-risk alternatives for adults.
Youth protection and adult harm reduction are complementary public health goals, and effective regulation should seek to achieve both simultaneously.
Treating all flavours, all packaging, or all nicotine products as equally problematic risks overlooking evidence that many adults who successfully move away from combustible cigarettes prefer non-tobacco flavours and require products that remain acceptable alternatives to smoking.
Regulation Should Be Proportionate
Internationally, nicotine regulation is moving toward more sophisticated, risk-based approaches.
Rather than relying solely on prohibition or treating all nicotine products identically, many policymakers are exploring frameworks based on product characteristics, toxicological profiles, nicotine strength, packaging standards, youth protections, and manufacturing quality.
This reflects the principle of risk-proportionate regulation: the highest-risk products should face the strongest controls, while lower-risk alternatives for adults who smoke should be regulated responsibly, not treated as though they pose the same risks as combustible cigarettes.
Looking Beyond Headlines
Nicotine pouches are neither a public health panacea nor simply another “industry ploy.”
Like many emerging nicotine products, they present both opportunities and challenges. The evidence supports robust youth protection, responsible product standards, ongoing scientific evaluation, and clear communication about relative risk.
Public health is best served when complex issues are presented with balance rather than binary narratives. As the evidence base continues to develop, discussions about nicotine pouches should reflect the full spectrum of current science—recognising both the risks that require regulation and the potential role these products may play in reducing the burden of combustible tobacco.
Source article here: https://med.stanford.edu/news/insights/2026/06/nicotine-pouches-addiction-tobacco-industry-latest-ploy.html
